Sfoglia per AUTORE
BARBUI A
Collezione AO Ordine Mauriziano

  

Items : 15

Seven Years of Culture Collection of Neisseria gonorrhoeae: Antimicrobial Resistance and Molecular Epidemiology. in Microbial drug resistance (Larchmont, N.Y.) / Microb Drug Resist. 2023 Mar;29(3):85-95. doi: 10.1089/mdr.2021.0483. Epub 2023 Feb 8.

2023
AOU Città della Salute di Torino
ASL Città di Torino
ASL VCO
AO Ordine Mauriziano

Lista F; Stefanelli P; Ciammaruconi A; Boros S; Ambrosio L; Soldato G; Casonato IC; Innocenti P; Latino MA; Riccobono E; Poletti F; Bonanno CL; De Francesco MA; Rotondi M; Mencacci A; Busetti M; Barbui AM; Stroppiana E; Prignano G; Vocale C; Fontana S; Dal Conte I; Ghisetti V; Cusini M; Carannante A; Vacca P;

Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2016 Nov 20;34(33):4015-4022. doi: 10.1200/JCO.2016.67.2980. Epub 2016 Oct 31.

2016
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano

Rambaldi A; Boschini C; Delaini F; Masciulli A; Pileri S; Tabanelli V; Bruna R; Chilosi M; Falorio S; Flenghi L; Frezzato M; Trentin L; Gini G; La Nasa G; Benedetti F; Ferreri AJ; Di Raimondo F; Castellino C; Negri G; Piccin A; Billio A; Zoli V; Zanni M; Mulé A; Corradini P; Patti C; Di Nicola M; Gritti G; Rossi A; et alii...

Life expectancy in follicular lymphoma is mainly determined by response to first LINE treatment: A LONG-TERM survey on 597 patients in Blood

2015
AO Ordine Mauriziano

Tarella C; Gueli A; Delaini F; Barbui AM; Bruna R; Caracciolo D; Gottardi D; Gritti G; Passera R; Ramadan S; Rossi A; Rambaldi A;

Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival. in PloS one / PLoS One. 2014 Sep 25;9(9):e106745. doi: 10.1371/journal.pone.0106745. eCollection 2014.

2014
AO Ordine Mauriziano
AOU Città della Salute di Torino

Tarella C; Gueli A; Delaini F; Rossi A; Barbui AM; Gritti G; Boschini C; Caracciolo D; Bruna R; Ruella M; Gottardi D; Passera R; Rambaldi A;

Long-term results of the phase III GITMO/FIL trial of CHOP-R versus R-HDS plus autograft in high-risk follicular lymphoma (FL) at diagnosis in Journal of Clinical Oncology

2014
AO Ordine Mauriziano

Magni M; Ladetto M; Gueli A; Passera R; Bruna R; Corradini P; Zoli V; Perrone T; Stelitano C; Rossini F; Castellino C; Gini G; Liberati AM; Musso M; Pulsoni A; Barbui AM; Patti C; Boccomini C; Benedetti F; Tarella C;

Intensified program including bendamustine, high dose therapy and autograft for patients with relapsed or resistant follicular non hodgkin lymphoma: Results from an exploratory gitil study in Hematological Oncology

2013
AO Ordine Mauriziano

Patti C; Mule' A; Barbui A; Tringali S; Costa A; Gueli A; Castellino C; Magni M; Dodero A; Leone M; Fabbiano F; Gallamini A; Corradini P; Gianni A; Tarella C; Rambaldi A; Scime' R;

The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy in American Journal of Hematology

2013
AO Ordine Mauriziano

Rambaldi A; Boschini C; Gritti G; Delaini F; Oldani E; Rossi A; Barbui AM; Caracciolo D; Ladetto M; Gueli A; De Crescenzo A; Passera R; Devizzi L; Patti C; Gianni AM; Tarella C;

The lymphocytes to monocytes ratio identifies a patient subgroup among high risk DLBCL that may benefit from upfront intensive treatment with autograft in Haematologica

2013
AO Ordine Mauriziano

Barbui AM; Masciulli A; Scarano M; Delaini F; Rossi A; Ladetto M; Corradini P; Di Nicola M; Patty C; Mulè A; Zanni M; Zoli V; Billio A; Gallamini A; Di Raimondo F; Ferreri AJM; Benedetti F; Leoni P; Semenzato G; Frezzato M; Flenghi L; Marchioli R; Barbui T; Gianni AM; Tarella C; Cortelazzo S; Rambaldi A;

Frequency and clinical outcome of primary refractory disease in nonhodgkin's lymphoma: A retrospective survey on 3,492 newly diagnosed patients undergoing first-line chemotherapy in Haematologica

2013
AO Ordine Mauriziano

Tarella C; Gueli A; Delaini F; Rossi A; Barbui A; Gritti G; Caracciolo D; Hu H; Gottardi D; Passera R; Rambaldi A;

Primary refractory disease in non-Hodgkin's lymphoma: A retrospective study on 3,952 newly diagnosed patients undergoing first-line chemotherapy in Blood

2012
AO Ordine Mauriziano

Tarella C; Gueli A; Delaini F; Rossi A; Barbui AM; Gritti G; Caracciolo D; Hu H; Gottardi D; Passera R; Rambaldi A;

The peripheral blood lymphocyte to monocyte ratio at diagnosis is a potent outcome predictor in diffuse large B-cell lymphoma treated with R-CHOP: A long-term analysis on 973 patients receiving chemotherapy with or without rituximab in Blood

2012
AO Ordine Mauriziano

Rambaldi A; Boschini C; Delaini F; Oldani E; Rossi A; Barbui AM; Gritti G; Caracciolo D; Ladetto M; Gueli A; De Crescenzo A; Passera R; Devizzi L; Gianni AM; Tarella C;

Male gender, quality of grafted cells, advanced age, rituximab and radiotherapy are the main factors that variously influence the occurrence of secondary malignancies following high-dose therapy and autograft: A GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) survey in 1,347 lymphoma patients in Blood

2009
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Tarella C; Passera R; Magni M; Rossi A; Benedetti F; Gueli A; Patti C; Parvis G; Ciceri F; Gallamini A; Cortelazzo S; Corradini P; Zoli V; Mule A; Crocchiolo R; Bosa M; Barbui A; Di Nicola M; Caracciolo D; Sorio M; Gianni AM; Rambaldi A;

High response rate with favorable survival projections in high-risk patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP-14 or early intensified chemotherapy with rituximab and autograft (R-HDS): Results of the interim analysis of a gitil prospective multicenter phase III study in Blood

2009
AO Ordine Mauriziano

Cortelazzo S; Tarella C; Gianni AM; Ladetto M; Zanni M; Corradini P; Di Nicola M; Patti C; Mulè A; Majolino I; Billio A; Gueli A; Di Raimondo F; Chiarenza A; Gallamini A; Ferreri A; Pizzolo G; Benedetti F; La Nasa G; Leoni P; Gini G; Trentin L; Rodeghiero F; Marchioli R; Barbui T; Barbui A; Rambaldi A;

Factors influencing the occurrence of secondary myelodysplastic syndrome/acute leukemia following high-dose therapy and autograft: A GITIL (Gruppo Italiano Terapie innovative nei linfomi) survey in 1,347 lymphoma patients in Haematologica

2009
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Tarella C; Passera R; Magni M; Rossi A; Gueli A; Benedetti F; Patti C; Parvis G; Ciceri F; Gallamini A; Cortelazzo S; Corradini P; Zoli V; Leone M; Bosa M; Barbui A; Di Nicola M; Boccadoro M; Sorio M; Gianni AM; Rambaldi A;

Histology and rituximab addition are the main factors influencing the long-term outcome in high-risk lymphoma following high-dose therapy and autograft: A 20-yr. Follow-up in 1,347 patients by gitil (gruppo italiano terapie innovative NEI Linfomi) in Haematologica

2009
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Tarella C; Di Nicola M; Rossi A; Caracciolo D; Passera R; Benedetti F; Patti C; Parvis G; Ciceri F; Castellino C; Cortelazzo S; Corradini P; Majolino I; Mule' A; Bosa M; Barbui A; Magni M; Boccadoro M; Sorio M; Rambaldi A; Gianni AM;